Prof. Backman will be using his expertise in nanoimaging and physic-chemical analysis of chromatin as well as the nano-imaging platform developed in his lab to develop and validate the ISOCT probe as well as EIBS related prediction rules for advanced stage adenomas in an attempt to elucidate the molecular mechanisms involved in metabolic reprogramming of cells. Prof. Backman will also be involved in the identification of secondary metabolic events as potential adenoma prevention strategy.
|Effective start/end date||3/5/18 → 2/28/23|
- Boston Medical Center (BMC ID 6610//R01CA224911-02)
- National Cancer Institute (BMC ID 6610//R01CA224911-02)